Overview

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.
Phase:
Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Pregabalin